Show simple item record

dc.contributor.authorMenon, Shyam
dc.contributor.authorHolt, Andrew
dc.contributor.authorFarmer, Adam D
dc.date.accessioned2024-06-04T15:12:16Z
dc.date.available2024-06-04T15:12:16Z
dc.date.issued2022-04-14
dc.identifier.citationMenon S, Holt A, Farmer AD. Intra-sphincteric botulinum toxin in the management of functional biliary pain. Endosc Int Open. 2022 Apr 14;10(4):E521-E527. doi: 10.1055/a-1784-0061en_US
dc.identifier.issn2364-3722
dc.identifier.doi10.1055/a-1784-0061
dc.identifier.pmid35433205
dc.identifier.urihttp://hdl.handle.net/20.500.14200/4772
dc.description.abstractBackground and study aims The management of functional biliary-type pain remains a clinical challenge. Intra sphincteric botulinum toxin putatively exerts an anti-spasmodic and anti-nociceptive effect. The objective of this study was to examine the clinical response to intra sphincteric botulinum toxin in patients with functional biliary-type pain. Patients and methods This was a cross-sectional (hypothesis-generating) study of prospectively collected data from patients referred to a tertiary center from 2014 to 2019. The efficacy of ampullary botulinum toxin injection for relief of pain was recorded at post-procedure outpatient review. Opioid analgesia, neuromodulatory medication, and frequency of hospital admissions were recorded. Results A total of 119 consecutive patients (109 women, 10 men, mean age 45 years; range 17-77) underwent 411 intra-sphincteric botulinum toxin injection procedures (mean 2 procedures; range 1-15). A total of 103 patients (87 %) had a significant improvement in pain on post-procedure review and 77 % and 76 % of patients were opioid and admission free, respectively. Of the patients, 59 % were prescribed tricyclic antidepressants (amitriptyline), 18 % duloxetine, 13 % pregabalin, and 3 % mirtazapine. Loss of response with the initial dose of botulinum toxin occurred in 56 % of patients. Pain control was reestablished in 80 % of patients in this cohort following botulinum toxin injection at a higher dose. Conclusions These data suggest that botulinum toxin may improve outcomes in patients with functional biliary pain. Further controlled studies are needed to clarify the role of Botox and neuromodulatory agents.en_US
dc.language.isoenen_US
dc.publisherThiemeen_US
dc.relation.urlhttps://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00025476en_US
dc.rightsThe Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.subjectGastroenterologyen_US
dc.titleIntra-sphincteric botulinum toxin in the management of functional biliary pain.en_US
dc.typeArticleen_US
dc.source.journaltitleEndoscopy International Openen_US
dc.source.volume10
dc.source.issue4
dc.source.beginpageE521
dc.source.endpageE527
dc.source.countryGermany
rioxxterms.versionNAen_US
dc.contributor.trustauthorMenon, Shyam
dc.contributor.trustauthorHolt, Andrew
dc.contributor.departmentLiveren_US
dc.contributor.departmentLiver Transplanten_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record